remeron tablets 30 mg (レメロン錠30mg)
organon - mirtazapine - yellow-red tablet, major axis: 13 mm, minor axis: 7 mm, thickness: 4.6 mm
pregeron 100mg capsule
ambica international corp. - pregabalin - capsule - 100mg
pregeron 100 mg capsule
n/a; importer: ambica international corporation; distributor: ambica international corporation - pregabalin - capsule - 100 mg
pushchair transport wheelchair, collapsible - transport wheelchair, collapsible
dejay medical & scientific pty ltd - 45052 - transport wheelchair, collapsible - transport wheelchair, collapsible
ei0 stroller - transport wheelchair, collapsible
dejay medical & scientific pty ltd - 45052 - transport wheelchair, collapsible - eio stroller/wheelchair that is transportable and collapsible
mirtazapine 30mg tablets
kent pharma (uk) ltd - mirtazapine - oral tablet - 30mg
mirtazapine tablet, film coated
ncs healthcare of ky, inc dba vangard labs - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine tablets, usp are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. the effectiveness of mirtazapine in hospitalized dep
mirtazapine tablet, film coated
remedyrepack inc. - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine tablets in the treatment of major depressive disorder was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of mirtazapine tablets
zispin soltab 45 mg orodispersible tablets
merck sharp & dohme ireland (human health) limited - mirtazapine - orodispersible tablet - 45 milligram(s) - other antidepressants; mirtazapine
zispin soltab 45mg orodispersible tablets
de pharmaceuticals - mirtazapine - orodispersible tablet - 45mg